Over the past few years, prostate-specific membrane antigen- (PSMA-) targeted radiotracers have been widely used in the diagnosis (68Ga-PSMA) and treatment (177Lu-PSMA) of prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.